Noul Co. Ltd.
Noul Co.,Ltd. engages in the in-vitro diagnosis and remote diagnosis business worldwide. It offers miLab, an AI-based blood diagnostic medical device that automates sample preparation, imaging, and analysis. The company also provides malaria diagnostics, blood cell morphology analysis, cancer morphology, immunohistochemistry services, and digital cervical cell analysis solution. Noul Co.,Ltd. was… Read more
Noul Co. Ltd. (376930) - Net Assets
Latest net assets as of June 2025: ₩10.61 Billion KRW
Based on the latest financial reports, Noul Co. Ltd. (376930) has net assets worth ₩10.61 Billion KRW as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩29.14 Billion) and total liabilities (₩18.53 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩10.61 Billion |
| % of Total Assets | 36.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 232.43 |
Noul Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Noul Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Noul Co. Ltd. (2019–2024)
The table below shows the annual net assets of Noul Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩20.17 Billion | -53.09% |
| 2023-12-31 | ₩42.99 Billion | +277.24% |
| 2022-12-31 | ₩11.40 Billion | +513.66% |
| 2021-12-31 | ₩1.86 Billion | +114.69% |
| 2020-12-31 | ₩-12.64 Billion | -176.11% |
| 2019-12-31 | ₩-4.58 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Noul Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7475008402000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩18.47 Billion | 91.60% |
| Other Components | ₩87.39 Billion | 433.30% |
| Total Equity | ₩20.17 Billion | 100.00% |
Noul Co. Ltd. Competitors by Market Cap
The table below lists competitors of Noul Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
American Eagle Gold Corp
PINK:AMEGF
|
$31.32 Million |
|
Electrotherm (India) Limited
NSE:ELECTHERM
|
$31.33 Million |
|
Conrad Asia Energy Ltd
AU:CRD
|
$31.33 Million |
|
Susquehanna Community Financial Inc
PINK:SQCF
|
$31.34 Million |
|
De Poan Pneumatic
TWO:1570
|
$31.32 Million |
|
PAPOUTSANIS SA NA.EO -54
F:Y2O
|
$31.31 Million |
|
CNG Vietnam JSC
VN:CNG
|
$31.31 Million |
|
Biotalys NV
BR:BTLS
|
$31.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Noul Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 42,988,949,230 to 20,168,109,990, a change of -22,820,839,240 (-53.1%).
- Net loss of 22,469,262,530 reduced equity.
- Other factors decreased equity by 351,576,710.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-22.47 Billion | -111.41% |
| Other Changes | ₩-351.58 Million | -1.74% |
| Total Change | ₩- | -53.09% |
Book Value vs Market Value Analysis
This analysis compares Noul Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ₩-439.22 | ₩1657.00 | x |
| 2020-12-31 | ₩-606.36 | ₩1657.00 | x |
| 2021-12-31 | ₩89.06 | ₩1657.00 | x |
| 2022-12-31 | ₩497.47 | ₩1657.00 | x |
| 2023-12-31 | ₩1163.53 | ₩1657.00 | x |
| 2024-12-31 | ₩545.87 | ₩1657.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Noul Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -111.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1403.05%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.87x
- Recent ROE (-111.41%) is above the historical average (-155.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-5.53 Billion |
| 2020 | 0.00% | -3039.09% | 0.02x | 0.00x | ₩-7.71 Billion |
| 2021 | -663.06% | -834.61% | 0.07x | 10.75x | ₩-12.50 Billion |
| 2022 | -120.05% | -2524.55% | 0.02x | 2.27x | ₩-14.82 Billion |
| 2023 | -37.97% | -597.00% | 0.05x | 1.29x | ₩-20.62 Billion |
| 2024 | -111.41% | -1403.05% | 0.04x | 1.87x | ₩-24.49 Billion |
Industry Comparison
This section compares Noul Co. Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $80,735,275,073
- Average return on equity (ROE) among peers: -13.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Noul Co. Ltd. (376930) | ₩10.61 Billion | 0.00% | 1.75x | $31.32 Million |
| NSN Co. Ltd (031860) | $102.59 Billion | 0.00% | 0.91x | $4.54 Million |
| JOONGANG DNM Co.Ltd (051980) | $24.46 Billion | -32.51% | 0.43x | $77.93 Million |
| GeneMatrix Inc (109820) | $32.32 Billion | -3.06% | 0.22x | $21.53 Million |
| Genoray Co. Ltd (122310) | $11.35 Billion | 17.59% | 1.51x | $24.43 Million |
| Green Cross Lab Cell Corporation (144510) | $457.79 Billion | -16.14% | 0.26x | $147.96 Million |
| Optipharm.CO.LTD (153710) | $25.14 Billion | -9.69% | 0.56x | $30.10 Million |
| Cytogen Inc (217330) | $48.58 Billion | -35.23% | 0.49x | $27.02 Million |
| U2Bio Co., Ltd. (221800) | $33.84 Billion | 38.88% | 0.51x | $84.13 Million |
| Gencurix Inc (229000) | $8.20 Billion | -110.48% | 0.13x | $21.11 Million |
| P&K Skin Research Center Co. Ltd (347740) | $63.07 Billion | 11.56% | 0.06x | $15.93 Million |